FDA Watch
Avsnitt

From Price Strategy to Enforcement Risk

Dela

In this third and final part of our series in collaboration with White & Case and BRGWayne chats with Lauren Papenhausen, Partner at White & Case's Boston office, and Edward Buthusiem, Managing Director at BRG. Together, they discuss pricing-related government enforcement risks and the legal frameworkcommercialization strategies under heightened enforcement scrutiny; internal investigations and distinguishing isolated issues from systemic compliance failures; board and audit committee oversight of pricing compliance and internal controls; emerging enforcement risks from state-level drug pricing regulation; and much more.

This episode and the rest of our series do not include the usual Headlines and Resources Links segments.

To subscribe or find out more information about our podcast, visit FDAWatch.net.

Want to be a sponsor, marketing partner, or guest, or provide feedback on the podcast? Email us ainfo@fdawatch.net. 

Music by Dvir Silver from Pixabay. 

Podden och tillhörande omslagsbild på den här sidan tillhör FDA Watch. Innehållet i podden är skapat av FDA Watch och inte av, eller tillsammans med, Poddtoppen.